BACKGROUND AND OBJECTIVES: This study examined the risks, predictors, and mortality implications of cerebrovascular disease events after kidney transplantation in a national cohort. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This analysis used United States Renal Data System registry data to study retrospectively Medicare-insured kidney transplant candidates (n = 51,504), recipients (n = 29,614), and recipients with allograft failure (n = 2954) in 1995 through 2002. New-onset cerebrovascular disease events including ischemic stroke, hemorrhagic stroke, and transient ischemic attacks were ascertained from billing records, and participants were followed until Medicare-end or December 31, 2002. Multivariable survival analysis was used to compare cerebrovascular disease event incidence and risk profiles among the study samples. RESULTS: The cumulative, 3-yr incidence of de novo cerebrovascular disease events after transplantation was 6.8% and was lower than adjusted 3-yr estimates of 11.8% on the waiting list and 11.2% after graft loss. In time-dependent regression, transplantation predicted a 34% reduction in subsequent, overall cerebrovascular disease events risk compared with remaining on the waiting list, whereas risk for cerebrovascular disease events increased >150% after graft failure. Similar relationships with transplantation and graft loss were observed for each type of cerebrovascular disease event. Smoking was a potentially preventable correlate of posttransplantation cerebrovascular disease events. Women were not protected. All forms of cerebrovascular disease event diagnoses after transplantation predicted increased mortality. CONCLUSIONS: Along with known benefits for cardiac complications, transplantation with sustained graft function seems to reduce risk for vascular disease events involving the cerebral circulation.
BACKGROUND AND OBJECTIVES: This study examined the risks, predictors, and mortality implications of cerebrovascular disease events after kidney transplantation in a national cohort. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This analysis used United States Renal Data System registry data to study retrospectively Medicare-insured kidney transplant candidates (n = 51,504), recipients (n = 29,614), and recipients with allograft failure (n = 2954) in 1995 through 2002. New-onset cerebrovascular disease events including ischemic stroke, hemorrhagic stroke, and transient ischemic attacks were ascertained from billing records, and participants were followed until Medicare-end or December 31, 2002. Multivariable survival analysis was used to compare cerebrovascular disease event incidence and risk profiles among the study samples. RESULTS: The cumulative, 3-yr incidence of de novo cerebrovascular disease events after transplantation was 6.8% and was lower than adjusted 3-yr estimates of 11.8% on the waiting list and 11.2% after graft loss. In time-dependent regression, transplantation predicted a 34% reduction in subsequent, overall cerebrovascular disease events risk compared with remaining on the waiting list, whereas risk for cerebrovascular disease events increased >150% after graft failure. Similar relationships with transplantation and graft loss were observed for each type of cerebrovascular disease event. Smoking was a potentially preventable correlate of posttransplantation cerebrovascular disease events. Women were not protected. All forms of cerebrovascular disease event diagnoses after transplantation predicted increased mortality. CONCLUSIONS: Along with known benefits for cardiac complications, transplantation with sustained graft function seems to reduce risk for vascular disease events involving the cerebral circulation.
Authors: J F Whiting; R S Woodward; E Y Zavala; D S Cohen; J E Martin; G G Singer; J A Lowell; M R First; D C Brennan; M A Schnitzler Journal: Transplantation Date: 2000-09-15 Impact factor: 4.939
Authors: Kevin C Abbott; Iman O Hypolite; Paul Hshieh; David Cruess; Allen J Taylor; Lawrence Y Agodoa Journal: Ann Epidemiol Date: 2002-02 Impact factor: 3.797
Authors: L Pou; M Brunet; C Cantarell; E Vidal; F Oppenheimer; V Monforte; J Vilardell; A Roman; J Martorell; L Capdevila Journal: Ther Drug Monit Date: 2001-02 Impact factor: 3.681
Authors: A M de Mattos; J Prather; A J Olyaei; Y Shibagaki; D S Keith; M Mori; D J Norman; T Becker Journal: Kidney Int Date: 2006-06-21 Impact factor: 10.612
Authors: Krista L Lentine; Mark A Schnitzler; Kevin C Abbott; Leiming Li; Huiling Xiao; Thomas E Burroughs; Steven K Takemoto; Lisa M Willoughby; Jeffrey A Gavard; Daniel C Brennan Journal: Clin J Am Soc Nephrol Date: 2005-12-28 Impact factor: 8.237
Authors: Mark Duncan Findlay; Jesse Dawson; David Alexander Dickie; Kirsten P Forbes; Deborah McGlynn; Terry Quinn; Patrick B Mark Journal: J Am Soc Nephrol Date: 2018-12-07 Impact factor: 10.121
Authors: Krista L Lentine; Mark A Schnitzler; Kevin C Abbott; Kosha Bramesfeld; Paula M Buchanan; Daniel C Brennan Journal: Clin J Am Soc Nephrol Date: 2009-06-18 Impact factor: 8.237
Authors: D A Axelrod; A S Naik; M A Schnitzler; D L Segev; V R Dharnidharka; D C Brennan; S Bae; J Chen; A Massie; K L Lentine Journal: Am J Transplant Date: 2016-03-31 Impact factor: 8.086
Authors: Tarek Alhamad; Daniel C Brennan; Zaid Brifkani; Huiling Xiao; Mark A Schnitzler; Vikas R Dharnidharka; David Axelrod; Dorry L Segev; Krista L Lentine Journal: Transplantation Date: 2016-05 Impact factor: 4.939
Authors: Vikas R Dharnidharka; Mark A Schnitzler; Jiajing Chen; Daniel C Brennan; David Axelrod; Dorry L Segev; Kenneth B Schechtman; Jie Zheng; Krista L Lentine Journal: Transpl Int Date: 2016-09-28 Impact factor: 3.782
Authors: Vikas R Dharnidharka; Abhijit S Naik; David Axelrod; Mark A Schnitzler; Huiling Xiao; Daniel C Brennan; Dorry L Segev; Henry Randall; Jiajing Chen; Bertram Kasiske; Krista L Lentine Journal: Transplantation Date: 2017-04 Impact factor: 4.939